Literature DB >> 33719426

One Atom Makes All the Difference: Getting a Foot in the Door between SOS1 and KRAS.

Juergen Ramharter1, Dirk Kessler1, Peter Ettmayer1, Marco H Hofmann1, Thomas Gerstberger1, Michael Gmachl1, Tobias Wunberg1, Christiane Kofink1, Michael Sanderson1, Heribert Arnhof1, Gerd Bader1, Klaus Rumpel1, Andreas Zöphel1, Renate Schnitzer1, Jark Böttcher1, Jonathan C O'Connell2, Rachel L Mendes2, David Richard2, Nikolai Pototschnig1, Irene Weiner1, Wolfgang Hela1, Katja Hauer1, Daniela Haering1, Lyne Lamarre1, Bernhard Wolkerstorfer1, Christian Salamon1, Patrick Werni1, Silvia Munico-Martinez1, Reiner Meyer1, Matthew D Kennedy1, Norbert Kraut1, Darryl B McConnell1.   

Abstract

KRAS, the most common oncogenic driver in human cancers, is controlled and signals primarily through protein-protein interactions (PPIs). The interaction between KRAS and SOS1, crucial for the activation of KRAS, is a typical, challenging PPI with a large contact surface area and high affinity. Here, we report that the addition of only one atom placed between Y884SOS1 and A73KRAS is sufficient to convert SOS1 activators into SOS1 inhibitors. We also disclose the discovery of BI-3406. Combination with the upstream EGFR inhibitor afatinib shows in vivo efficacy against KRASG13D mutant colorectal tumor cells, demonstrating the utility of BI-3406 to probe SOS1 biology. These findings challenge the dogma that large molecules are required to disrupt challenging PPIs. Instead, a "foot in the door" approach, whereby single atoms or small functional groups placed between key PPI interactions, can lead to potent inhibitors even for challenging PPIs such as SOS1-KRAS.

Entities:  

Year:  2021        PMID: 33719426     DOI: 10.1021/acs.jmedchem.0c01949

Source DB:  PubMed          Journal:  J Med Chem        ISSN: 0022-2623            Impact factor:   7.446


  3 in total

1.  Selective inhibitors of SARM1 targeting an allosteric cysteine in the autoregulatory ARM domain.

Authors:  Hannah C Feldman; Elisa Merlini; Carlos Guijas; Kristen E DeMeester; Evert Njomen; Ellen M Kozina; Minoru Yokoyama; Ekaterina Vinogradova; Holly T Reardon; Bruno Melillo; Stuart L Schreiber; Andrea Loreto; Jacqueline L Blankman; Benjamin F Cravatt
Journal:  Proc Natl Acad Sci U S A       Date:  2022-08-22       Impact factor: 12.779

Review 2.  The Role of Wild-Type RAS in Oncogenic RAS Transformation.

Authors:  Erin Sheffels; Robert L Kortum
Journal:  Genes (Basel)       Date:  2021-04-28       Impact factor: 4.096

3.  Design and Discovery of MRTX0902, a Potent, Selective, Brain-Penetrant, and Orally Bioavailable Inhibitor of the SOS1:KRAS Protein-Protein Interaction.

Authors:  John M Ketcham; Jacob Haling; Shilpi Khare; Vickie Bowcut; David M Briere; Aaron C Burns; Robin J Gunn; Anthony Ivetac; Jon Kuehler; Svitlana Kulyk; Jade Laguer; J David Lawson; Krystal Moya; Natalie Nguyen; Lisa Rahbaek; Barbara Saechao; Christopher R Smith; Niranjan Sudhakar; Nicole C Thomas; Laura Vegar; Darin Vanderpool; Xiaolun Wang; Larry Yan; Peter Olson; James G Christensen; Matthew A Marx
Journal:  J Med Chem       Date:  2022-07-14       Impact factor: 8.039

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.